Bob Mauch'un ücretlendirmesi Cencora'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	US$8m	US$975k	US$2b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	US$6m	US$850k	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	US$6m	US$800k	US$2b
Jun 30 2021	n/a	n/a	-US$4b
Mar 31 2021	n/a	n/a	-US$4b
Dec 31 2020	n/a	n/a	-US$3b
Sep 30 2020	US$4m	US$700k	-US$3b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	n/a	n/a	US$649m
Sep 30 2019	US$4m	US$675k	US$855m
Jun 30 2019	n/a	n/a	US$956m
Mar 31 2019	n/a	n/a	US$930m
Dec 31 2018	n/a	n/a	US$1b
Sep 30 2018	US$3m	US$675k	US$2b

Tazminat ve Piyasa: Bob 'nin toplam tazminatı ($USD 7.70M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 13.04M ).

Tazminat ve Kazançlar: Bob 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Bob Mauch (57 yo)

2yrs

Görev süresi

US$7,697,850

Tazminat

Dr. Robert P. Mauch, PharmD, Ph D., also known as Bob, is an Executive Vice President at Cencora, Inc. (formerly known as AmerisourceBergen Corporation) since February 2015 and served as its Group Presiden...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Steven Collis	Executive Chairman	13.4yrs	US$17.51m	0.15% $ 62.7m
Robert Mauch	President	2yrs	US$7.70m	0.012% $ 5.4m
James Cleary	Executive VP & CFO	5.9yrs	US$5.45m	0.058% $ 25.1m
Elizabeth Campbell	Executive VP & Chief Legal Officer	3.1yrs	US$4.03m	0.0042% $ 1.8m
Lazarus Krikorian	Senior VP	12.8yrs	Veri yok	0.010% $ 4.4m
Bennett Murphy	Senior Vice President of Investor Relations	no data	Veri yok	Veri yok
Jennifer Dubas	Senior VP & Chief Compliance Officer	no data	Veri yok	Veri yok
Silvana Battaglia	Executive VP & Chief Human Resources Officer	5.8yrs	US$3.48m	0.0056% $ 2.4m
Ann Anaya	Senior VP and Chief Diversity Equity & Inclusion Officer	2.8yrs	Veri yok	Veri yok
J. Quinn	VP & Corporate Treasurer	no data	Veri yok	Veri yok
Brian Nightengale	President of Good Neighbor Pharmacy	8.2yrs	Veri yok	Veri yok
Kourosh Pirouz	VP, Associate General Counsel & Secretary	no data	Veri yok	Veri yok

4.4yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: COR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Steven Collis	Executive Chairman	13.4yrs	US$17.51m	0.15% $ 62.7m
Robert Mauch	President	no data	US$7.70m	0.012% $ 5.4m
Lauren Tyler	Independent Director	less than a year	Veri yok	Veri yok
Richard Gochnauer	Independent Director	16.1yrs	US$300.10k	0.011% $ 4.9m
Mark M. Durcan	Lead Independent Director	9.1yrs	US$380.05k	0.010% $ 4.3m
Lon Greenberg	Independent Director	11.4yrs	US$332.60k	0.0057% $ 2.5m
Kathleen Hyle	Independent Director	14.4yrs	US$320.10k	0.011% $ 4.6m
Dennis Nally	Independent Director	4.8yrs	US$375.36k	0.0044% $ 1.9m
Ornella Barra	Director	9.8yrs	Veri yok	Veri yok
Henry McGee	Independent Director	19.9yrs	US$320.10k	0.0077% $ 3.3m
Lorence Kim	Independent director	2yrs	US$397.33k	0.000090% $ 38.8k
Redonda Miller	Independent Director	1.8yrs	US$311.82k	0.00080% $ 344.9k

9.4yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: COR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.4 yıldır).

Cencora Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chairman notifies of intention to sell stock

Chairman notifies of intention to sell stock

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Chairman notifies of intention to sell stock

Chairman notifies of intention to sell stock

Insider exercised options and sold US$3.5m worth of stock

Recent updates

Cencora, Inc. to Report Q4, 2024 Results on Nov 06, 2024

Chairman notifies of intention to sell stock

Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly

Cencora: Credentials To Die For, But Underlying Issues Make Case For 'Hold' Rating

Chairman notifies of intention to sell stock

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Third quarter dividend of US$0.51 announced

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cencora, Inc. Declares Quarterly Cash Dividend, Payable on August 26, 2024

Chairman notifies of intention to sell stock

Market Participants Recognise Cencora, Inc.'s (NYSE:COR) Earnings

Cencora, Inc. to Report Q3, 2024 Results on Jul 31, 2024

Cencora: Potential Exists, But Ambiguous Valuations And Data Breach Risks Are Concerning

Are Investors Undervaluing Cencora, Inc. (NYSE:COR) By 43%?

Chairman notifies of intention to sell stock

Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly

Insider exercised options and sold US$3.5m worth of stock

Chairman exercised options and sold US$1.4m worth of stock

Do Cencora's (NYSE:COR) Earnings Warrant Your Attention?

Second quarter dividend of US$0.51 announced

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on May 24, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cencora, Inc. (NYSE:COR) announces an Equity Buyback for $2,000 million worth of its shares.

Executive VP & COO exercised options and sold US$4.9m worth of stock

Cencora, Inc. to Report Q2, 2024 Results on May 01, 2024

Investors Interested In Cencora, Inc.'s (NYSE:COR) Earnings

Cencora Remains Chronically Undervalued, With Material Growth Potential

Chairman exercised options and sold US$1.6m worth of stock

Cencora, Inc.'s (NYSE:COR) Intrinsic Value Is Potentially 53% Above Its Share Price

Cencora, Inc. Reaffirms Guidance for Year 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora (NYSE:COR) Seems To Use Debt Quite Sensibly

Cencora’s FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products

Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There

First quarter dividend of US$0.51 announced

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.0% to US$235

Consensus EPS estimates fall by 14%

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on February 26, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc. to Report Q1, 2024 Results on Jan 31, 2024

Cencora, Inc.'s (NYSE:COR) Business Is Yet to Catch Up With Its Share Price

Cencora: Continued Economic Value On The Table Across All Investment Horizons

Chairman recently sold US$8.7m worth of stock

A Look At The Fair Value Of Cencora, Inc. (NYSE:COR)

Chairman exercised options and sold US$3.1m worth of stock

Insider recently sold US$2.0m worth of stock

Executive VP & CFO exercised options and sold US$3.1m worth of stock

Cencora (NYSE:COR) Is Paying Out A Larger Dividend Than Last Year

Cencora, Inc. Declares Quarterly Dividend, Payable November 27, 2023

Is Cencora (NYSE:COR) A Risky Investment?

Full year 2023 earnings: EPS misses analyst expectations

Cencora: New Name, Same Old Economic Leverage, Reiterate Buy

Chairman exercised options and sold US$2.7m worth of stock

Cencora, Inc. to Report Q4, 2023 Results on Nov 02, 2023

Insider exercised options and sold US$2.0m worth of stock

Now 20% undervalued after recent price drop

Chairman exercised options and sold US$1.0m worth of stock

Now 21% undervalued

Amerisourcebergen Corporation Elects Werner Baumann and Lauren Tyler to Its Board of Directors

Chairman notifies of intention to sell stock

AmerisourceBergen Corporation Declares Quarterly Cash Dividend, Payable on August 28, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 34% Below Their Intrinsic Value Estimate

AmerisourceBergen: Great Company, Wrong Price (Rating Downgrade)

Chairman notifies of intention to sell stock

AmerisourceBergen Corporation to Report Q3, 2023 Results on Aug 02, 2023

Insider exercised options and sold US$3.0m worth of stock